James Mastrianni
Neurology · Chicago, ILNPI 1821149808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,525 of the $6,640 with a category attached, or 98.3%. Ionis Pharmaceuticals, Inc. accounts for 67.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $4,500, more than ten times the $40 reported in 2019.
Across 8 payments — averaging $830.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ionis Pharmaceuticals, Inc.$5K
- Eisai Inc.$2K
- Genentech, Inc.$40
- Biogen$34
- Blueprint Medicines Corporation$25
Across 12 payments — averaging $18,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$187K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- Genentech, Inc.$19K
What the payments were for
- Consulting fees$6,52598%
- Food & beverage$751%
- Education$401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ionis Pharmaceuticals, Inc. | 2 | $4,500 |
| Eisai Inc. | 2 | $2,041 |
| Genentech, Inc. | 1 | $40 |
| Biogen | 2 | $34 |
| Blueprint Medicines Corporation | 1 | $25 |
How this compares
$6,640 in reported general payments places this provider in the 75th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 15 | $9,757 |
| Rivastigmine | 25 | $7,859 |
| Memantine Hcl | 137 | $4,258 |
| Donepezil Hcl | 330 | $4,246 |
| Galantamine ErGalantamine Hbr | 32 | $3,220 |
| Memantine Hcl ErMemantine Hcl | 30 | $2,023 |
| Sertraline Hcl | 143 | $1,470 |
| Quetiapine Fumarate | 65 | $1,388 |
| Mirtazapine | 17 | $713 |
| Trazodone Hcl | 42 | $407 |
| Levetiracetam | 18 | $336 |
| Rosuvastatin Calcium | 16 | $239 |
| Famotidine | 16 | $190 |
| Amlodipine Besylate | 16 | $164 |
| Gabapentin | 13 | $149 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chicago
- Augusto MiravalleChicago$1.4M
- Adil JavedChicago$584K
- Danny BegaChicago$442K
- Michael SmithChicago$382K
- Dusan StefoskiChicago$294K
- Veronica CiprianiChicago$289K
- Thomas ShoemakerChicago$278K
- Bruce CohenChicago$276K
- Margaret ParkChicago$245K
- Leonard Verhagen MetmanChicago$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.